# Cephalexin for Oral Suspension, USP, 125 mg Class II – Retail Level Recall - CUSTOMER CARE TALK TRACK

# 

**Background Information:** NCQA made an update to their standard requesting communication be sent to members and prescribers affected by any recall classified as a Class II by the FDA except for wholesale level recalls. Communication is being sent to members and prescribers of NCQA delegated clients to inform them of the limited recall. **The distributor is not requiring any action on the part of consumers for these recalls.**

**This recall affects:**

|  |  |  |
| --- | --- | --- |
| **Product** | **NDC #** | **Lot #/Exp. Date** |
| Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed) | 67877-0544-88 | 23142342 exp. 06/30/2025  23142708 exp. 07/31/2025  23144035 exp. 10/31/2025  23144270 exp. 11/30/2025  24140026 exp. 12/31/2025 |
| Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed) | 67877-0544-68 | 23142343 exp. 06/30/2025 23143526 exp. 09/30/2025 23144036 exp. 10/31/2025 23144269 exp. 11/30/2025 24140027 exp. 12/31/2025 24144282 exp. 10/31/2026 |

# Customer Care Talk Track:

\*\* Please ensure to disposition all recall calls to code “**1116**” \*\*

|  |  |  |
| --- | --- | --- |
| **Q#** | **Question** | **Answer** |
| **1** | **Why did I receive a recall notice?** | Our records indicate that you may have recently received a prescription for a product affected by a limited recall from your retail pharmacy.  For more information, call the distributor listed on the letter or visit their website. You may also call the United States Food and Drug Administration (FDA) toll-free at 1‑888‑INFO-FDA (1‑888-463-6332) or visit [www.fda.gov](http://www.fda.gov). |
| **2** | **May I return the rest of the recalled product that I have?** | The distributor is not requiring any action on the part of consumers for these recalls. |
| **3** | **Should I stop using the recalled product?** | Please contact your prescriber with any questions or concerns about this recall or your use of the product. |

Additional Information:

Event Details

**Event ID:**

96912

**Voluntary / Mandated:**

Voluntary: Firm initiated

**Product Type:**

Drugs

**Initial Firm Notification of Consignee or Public:**

Letter

**Status:**

Ongoing

**Distribution Pattern:**

Nationwide in the USA.

**Recalling Firm:**

Ascend Laboratories, LLC  
339 Jefferson Rd Ste 101  
Parsippany, NJ 07054-3707  
United States

**Press Release URL(s):**

Press Release Not Issued For This Recall

**Recall Initiation Date:**

5/23/2025

**Center Classification Date:**

6/12/2025

**Date Terminated:**

N/A

**\*N/A -***Not Available*

Product Details

| **#** | **Product Description** | **Recall Number** | **Classification** | **Code Information** | **Product Quantity** | **Reason for Recall** |
| --- | --- | --- | --- | --- | --- | --- |
| 1 | Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascent Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-544-88 | D-0468-2025 | Class II | Lot #: 23141828, 23141829, Exp Date: 5/31/2025; 23142342, Exp Date: 6/30/2025; 23142708, Exp Date: 7/31/2025; 23144035, Exp Date: 10/31/2025; 23144270, Exp Date: 11/302025; 24140026, Exp Date: 12/31/2025 | 48,936 - 100 mL bottles | Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct. |
| 2 | Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascent Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-544-68 | D-0469-2025 | Class II | Lot #: 23142343, Exp Date: 6/30/2025; 23143526, Exp Date: 9/30/2025; 23144036, Exp Date: 10/31/2025; 23144269, Exp Date: 11/30/2025; Lot 24140027, Exp Date: 12/31/2025; 24144282, Exp Date: 10/31/2026 | 10,620 - 200 mL bottles | Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct. |

Update History

**There is no history available for products in this event**

[Top of the Document](#_top)

Not To Be Reproduced Or Disclosed to Others Without Prior Written Approval

**ELECTRONIC DATA = OFFICIAL VERSION / PAPER COPY = INFORMATIONAL ONLY**